Induction of estrogen receptor-α and -β activities by synthetic progestins

References

• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–59
   PubMed Web of Science ®Google Scholar
• Pike M, Henderson BE, Krailo MD, et al. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 1983; 2: 926–9
   PubMed Web of Science ®Google Scholar
• Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992; 52: 6539–46
   PubMed Web of Science ®Google Scholar
• Kalkhoven E, Kwakkenbos-Isbrücker L, de Laat SW, et al. Synthetic progestins induce proliferation of breast cancer cell lines via the progesterone or estrogen receptor. Mol Cell Endocrinol 1994; 102: 45–52
   PubMed Web of Science ®Google Scholar
• Lin VCL, Ng EH, Aw SE, et al. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res 1999; 5: 395–403
   PubMedGoogle Scholar
• Byrne MJ, Gebski V, Forbes J, et al. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. J Clin Oncol 1997; 15: 3141–8
   PubMed Web of Science ®Google Scholar
• Hultborn R, Johanssonterje I, Bergh J, et al. Second line endocrine treatment of advanced breast cancer: a randomized cross-over study of MPA and amino-glutethimide. Acta Oncol 1996; 35: 75–81
   PubMed Web of Science ®Google Scholar
• Graham JD, Roman SD, MaGowan E, et al. Preferential stimulation of human progesterone receptor B expression by estrogen in T47-D human breast cancer cells. J Biol Chem 1995; 270: 30693–700
   PubMed Web of Science ®Google Scholar
• Alexander IE, Shine J, Sutherland RL. Progestin regulation of estrogen receptor messenger RNA in human breast cancer cells. Mol Endocrinol 1990; 4: 821–8
   PubMedGoogle Scholar
• Poulin R, Baker D, Poirier D, et al. Multiple actions of synthetic progestins on the growth of ZR-75–1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Res Treat 1990; 17: 197–210
   Google Scholar
• Brandenberger AW, Tee MK, Lee JY, et al. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. J Clin Endocrinol Metab 1997; 82: 3509–12
   PubMed Web of Science ®Google Scholar
• Speirs V, Malone C, Walton DS, et al. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 1999; 59: 5421–4
   PubMed Web of Science ®Google Scholar
• Fuqua SA, Schiff R, Parra I, et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 1999; 59: 5425–8
   PubMed Web of Science ®Google Scholar
• Speirs V, Parkers AT, Kerin MJ, et al. Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?. Cancer Res 1990; 59: 525–8
   Google Scholar
• Leygue E, Dotzlaw H, Watson PH, et al. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res 1999; 59: 1175–9
   Google Scholar
• Fiorelli G, Picariello L, Martinetti V, et al. Functional estrogen receptor β in colon cancer cells. J Biochem Biophys Res Commun 1999; 261: 521–7
   PubMed Web of Science ®Google Scholar
• Carrol RS, Zhang J, Black PM. Expression of estrogen receptors α and β in human meningiomas. J Neurooncol 1999; 42: 109–16
   PubMedGoogle Scholar
• Kasid A, Lippman ME. Estrogen and oncogene mediated growth regulation of human breast cancer cells. J Steroid Biochem 1987; 27: 465–70
   PubMedGoogle Scholar
• Estrogen-Antiestrogen Action and Breast Cancer Therapy, VC Jordan. University of Wisconsin Press, Madison 1986; 132–43
   Google Scholar
• Weisz A, Bresciani F. Estrogen regulation of proto-oncogenes coding for nuclear proteins. Crit Rev Oncogen 1993; 4: 361–88
   PubMed Web of Science ®Google Scholar
• Planas-Silva MD, Weinberg RA. Estrogen dependent cyclinE–cdk2 activation through p21 redistribution. Mol Cell Biol 1997; 17: 4059–69
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Hamilton JA, Lee CS, et al. Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T47-D human breast cancer cell cycle progression. Mol Cell Biol 1993; 13: 3577–87
   PubMed Web of Science ®Google Scholar
• Kumar V, Green S, Staub A, et al. Localisation of the estradiol-binding domains of the human estrogen receptor. EMBOJ 1986; 5: 2231–6
   PubMed Web of Science ®Google Scholar
• Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925–30
   PubMed Web of Science ®Google Scholar
• Pettersson K, Grandien K, Kuiper GG, et al. Mouse estrogen receptor beta forms estrogen response element binding heterodimers with estrogen receptor alpha. Mol Endocrinol 1997; 11: 1486–96
   PubMed Web of Science ®Google Scholar
• Hall JM, McDonnell DP. The estrogen receptor-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogen and antiestrogens. Endocrinology 1999; 140: 5566–78
   PubMed Web of Science ®Google Scholar
• Fuhrmann U, Slater EP, Fritzemeier KH. Characterisation of the novel progestin gestodene by receptor binding studies and transactivation assays. Contraception 1995; 51: 45–52
   PubMedGoogle Scholar
• Haller DG, Glick JH. Progestational agents in advanced breast cancer: an overview. Semin Oncol 1986; 13: 2–8
   PubMed Web of Science ®Google Scholar
• Byrne MJ, Gebski V, Forbes J, et al. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. J Clin Oncol 1997; 3: 3141–8
   Google Scholar
• Hultborn R, Johanssonterje I, Bergh J, et al. Second-line endocrine treatment of advanced breast cancer: a randomized cross-over study of medroxyprogesterone acetate and aminoglutethimide. Acta Oncol 1996; 35: 75–9
   PubMed Web of Science ®Google Scholar
• Poulin R, Dufour JM, Labrie F. Progestin inhibition of estrogen-dependent proliferation in ZR-75–1 human breast cancer cells: antagonism by insulin. Breast Cancer Res Treat 1989; 13: 265–76
   PubMed Web of Science ®Google Scholar
• Jordan VC, Jeng MH, Cathenno WH, et al. The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer 1993; 71: 1501–5
   PubMed Web of Science ®Google Scholar
• Huggins C, Yang NC. Induction and extinction of mammary cancer. Science 1962; 137: 257–62
   PubMed Web of Science ®Google Scholar
• Asselin J, Kelly PA, Caron MG, et al. Control of hormone receptor levels and growth of 7,12-dimethylbenzanthracene-induced mammary tumors by estrogen, progesterone, and prolactin. Endocrinology 1977; 101: 666–71
   PubMed Web of Science ®Google Scholar
• Schoonen WG, Joosten JW, Klosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives on cell growth of human breast tumor cells. J Steroid Biochem Mol Biol 1995; 55: 439–44
   PubMedGoogle Scholar
• Alexieva-Figusc J, Teulings FA, Hop WC, et al. Steroid receptors in megestrol acetate therapy. Rec Results Cancer Res 1984; 91: 253–8
   PubMedGoogle Scholar
• Ettinger DS, Allegra J, Bertino JR, et al. Megestrol acetate vs. tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol 1986; 13: 9–14
   PubMed Web of Science ®Google Scholar
• Raynaud JP, Ojasoo T, Labrie F. Steroid agonists and antagonists. Mechanism of Steroid Action, GP Lewis, M Grisburg. MacMillan Press, London 1981; 145–58
   Google Scholar
• Van Kordelaar JM, Vermorken AJ, de Weerd CJ. Interaction of contraceptive progestins and related compounds with the estrogen receptor. Acta Androcr Copenh 1975; 78: 165–79
   Google Scholar
• Vilchis F, Chavez B, Perez AE, et al. Evidence that a non-aromatizable metabolite of norethisterone induces estrogen-dependent pituitary progesterone receptors. J Steroid Biochem 1986; 24: 525–31
   PubMedGoogle Scholar
• Larrea F, Vilchis F, Chavez B, et al. The metabolism of 19-nor contraceptive progestins modulates their biological activity at the neuroendocrine level. J Steroid Biochem 1987; 27: 657–63
   PubMedGoogle Scholar
• Fortunati N, Fissore F, Comba A. Sex steroid-binding protein and its membrane receptor in estrogen-dependent breast cancer: biological and pathophysiological impact. Horm Res 1996; 45: 202–6
   PubMedGoogle Scholar
• Maggi R, Poletti A, Casulari LA, et al. Effects and metabolism of steroid hormones in human neuroblastoma cells. Steroids 1998; 63: 257–62
   PubMedGoogle Scholar
• Van der Brule FA, Engel J, Stetler-Stevenson WG, et al. Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells. Int J Cancer 1992; 52: 653–7
   PubMedGoogle Scholar